CTNNB1 Gene Mutations, Pituitary Transcription Factors, and MicroRNA Expression Involvement in the Pathogenesis of Adamantinomatous Craniopharyngiomas

Genes involved in formation/development of the adenohypophysis, CTNNB1 gene, and microRNAs might be implicated in the craniopharyngioma pathogenesis. The objective of this study is to perform the molecular analysis of HESX1, PROP1, POU1F1, and CTNNB1 genes and evaluate a panel of miRNA expression in craniopharyngioma. We also verified whether the presence of CTNNB1 mutation is associated with clinical findings and miRNA expression. The study included 16 patients with adamantinomatous craniopharyngioma (nine children and seven adults; eight females and eight males; 6–55 years, median 15.5 years). DNA, RNA, and cDNA were obtained from craniopharyngioma and normal pituitaries. DNA was also extracted from peripheral blood of healthy subjects. All genes were amplified by polymerase chain reaction and direct sequenced. Relative quantification of miRNA expression was calculated using the 2−ΔΔCt method. We found no mutations in HESX1, PROP1, and POU1F1 genes and four polymorphisms in PROP1 gene which were in Hardy–Weinberg equilibrium and had similar allelic frequencies in craniopharyngioma and controls. We found seven different mutations in CTNNB1 in eight of 16 patients. Younger patients presented more frequently CTNNB1 mutation than adults. We observed hyperexpression of miR-150 (1.7-fold); no different expression of miR-16-1, miR-21, and miR23a; and an underexpression of miR-141, let-7a, miR-16, miR-449, miR-145, miR-143, miR-23b, miR-15a, and miR-24-2 (ranging from −7.5 to −2.5-fold; p = 0.02) in craniopharyngioma. There was no association between tumor size or the recurrence and the presence of CTNNB1mutations. miR-16 and miR-141 were underexpressed in craniopharyngioma presenting CTNNB1 mutations. miR-23a and miR24-2 were hyperexpressed in patients who underwent only one surgery. Mutations or polymorphisms in pituitary transcription factors are unlikely to contribute to the adamantinomatous craniopharyngioma pathogenesis, differently of CTNNB1 mutations. Our data suggest the potential involvement of the deregulation of miRNA expression in the craniopharyngioma pathogenesis and outcome and also that the miRNA could modulate the Wnt signaling pathway in craniopharyngioma tumorigenesis.

[1]  B. Hogan,et al.  Formation of Rathke's pouch requires dual induction from the diencephalon. , 1998, Development.

[2]  P. Kleihues,et al.  Correlation of clinical and pathological features in surgically treated craniopharyngiomas. , 1990, Journal of neurosurgery.

[3]  S. Camper,et al.  The Ames dwarf gene, df, is required early in pituitary ontogeny for the extinction of Rpx transcription and initiation of lineage-specific cell proliferation. , 1996, Molecular endocrinology.

[4]  Arianna Bottoni,et al.  miR‐15a and miR‐16‐1 down‐regulation in pituitary adenomas , 2005, Journal of cellular physiology.

[5]  I. Blümcke,et al.  Target Gene Activation of the Wnt Signaling Pathway in Nuclear β‐Catenin Accumulating Cells of Adamantinomatous Craniopharyngiomas , 2009, Brain pathology.

[6]  M. Byrom,et al.  Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis , 2005, Nucleic acids research.

[7]  V. Prabhu,et al.  The pathogenesis of craniopharyngiomas , 2005, Child's Nervous System.

[8]  J. Martinez-Barbera,et al.  Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse , 1998, Nature Genetics.

[9]  Gol'dberg Gm,et al.  Squamous cell nests of the pituitary gland as related to the origin of craniopharyngiomas. A study of their presence in the newborn and infants up to age four. , 1960, Archives of pathology.

[10]  S. Hirohashi,et al.  Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. , 2002, The American journal of pathology.

[11]  S. Hirohashi,et al.  Short Communication Craniopharyngiomas of Adamantinomatous Type Harbor -Catenin Gene Mutations , 2002 .

[12]  I. Blümcke,et al.  Nuclear β-Catenin Accumulation as Reliable Marker for the Differentiation Between Cystic Craniopharyngiomas and Rathke Cleft Cysts: A Clinico-Pathologic Approach , 2006, The American journal of surgical pathology.

[13]  A. Latronico,et al.  Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene. , 1999, The Journal of clinical endocrinology and metabolism.

[14]  Y. Nobukuni,et al.  Mutations in the Pit-1 gene in children with combined pituitary hormone deficiency. , 1992, Biochemical and biophysical research communications.

[15]  G. Goldberg,et al.  Squamous cell nests of the pituitary gland as related to the origin of craniopharyngiomas. A study of their presence in the newborn and infants up to age four. , 1960, Archives of pathology.

[16]  Wei Wu,et al.  Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism , 1996, Nature.

[17]  R. Fahlbusch,et al.  Common mutations of β-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region , 2005, Acta Neuropathologica.

[18]  F. Saggioro,et al.  MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. , 2009, The Journal of clinical endocrinology and metabolism.

[19]  George A Calin,et al.  Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas , 2007, Journal of cellular physiology.

[20]  C. Roth,et al.  Appetite‐Regulating Hormone Changes in Patients With Craniopharyngioma , 2011, Obesity.

[21]  Larry W. Swanson,et al.  Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1 , 1990, Nature.

[22]  Chen Liu,et al.  beta-Catenin is expressed aberrantly in tumors expressing shadow cells. Pilomatricoma, craniopharyngioma, and calcifying odontogenic cyst. , 2003, American journal of clinical pathology.

[23]  L. Olson,et al.  Temporal regulation of a paired-like homeodomain repressor/TLE corepressor complex and a related activator is required for pituitary organogenesis. , 2001, Genes & development.

[24]  W. Paulus,et al.  Lack of chromosomal imbalances in adamantinomatous and papillary craniopharyngiomas , 2003, Journal of neurology, neurosurgery, and psychiatry.

[25]  Douglas C. Miller,et al.  Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. , 1994, Neurosurgery.

[26]  D. Iliopoulos,et al.  MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling. , 2009, Cancer research.

[27]  M. Garrè,et al.  Craniopharyngioma: modern concepts in pathogenesis and treatment , 2007, Current opinion in pediatrics.

[28]  Anindya Dutta,et al.  MicroRNAs in cancer. , 2009, Annual review of pathology.

[29]  Hélio Rubens Machado,et al.  Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. , 2009, Arquivos brasileiros de endocrinologia e metabologia.

[30]  K. Tachibana,et al.  Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma , 2004, The Journal of pathology.

[31]  I. Blümcke,et al.  Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling , 2010, Acta Neuropathologica.

[32]  S. Mackem,et al.  Rpx: a novel anterior-restricted homeobox gene progressively activated in the prechordal plate, anterior neural plate and Rathke's pouch of the mouse embryo. , 1996, Development.

[33]  T. Lúcas,et al.  Hypothalamic‐pituitary dysfunction in patients with craniopharyngioma , 1995, Clinical endocrinology.

[34]  J. Warner,et al.  Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long‐term follow‐up , 2005, Clinical endocrinology.

[35]  I. Bossis,et al.  Pituitary magnetic resonance imaging in 15 patients with Prop1 gene mutations: pituitary enlargement may originate from the intermediate lobe. , 2004, The Journal of clinical endocrinology and metabolism.

[36]  J. Honegger,et al.  Surgical treatment of craniopharyngiomas: experience with 168 patients. , 1999, Journal of neurosurgery.

[37]  H. Abe,et al.  Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay , 1998, Acta Neuropathologica.

[38]  E. Friedman,et al.  Clonal composition of human adamantinomatous craniopharyngiomas and somatic mutation analyses of the patched (PTCH), Gsα and Gi2α genes , 2001, Neuroscience Letters.

[39]  M. Rosenfeld,et al.  Homeodomain-Mediated β-Catenin-Dependent Switching Events Dictate Cell-Lineage Determination , 2006, Cell.

[40]  E. Friedman,et al.  Comparative genomic hybridization analysis of craniopharyngiomas. , 2003, Journal of neurosurgery.

[41]  Hans Clevers,et al.  Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.

[42]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[43]  R. Nusse,et al.  The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.